Home Efficacy & Safety Chemotherapy-induced anemia
Illustrative background image
Chemotherapy-induced anemia

Chemotherapy-induced anemia

Anemia due to chemotherapy in patients with cancer1

PROCRIT® is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

PROCRIT® has not been shown to improve quality of life, fatigue, or patient well-being.

PROCRIT® is not indicated for use:

In anemic patients with cancer with non-myeloid malignancies receiving myelosuppressive chemotherapy

Change in mean Hb values by week on study2

Graph Change in mean Hb values by week on study
Hb=hemoglobin.

Reduces the need for transfusions1,2

Proportion of patients transfused, Week 5 through Week 16 or end of study

Graph Reduces the need for transfusions
Graph Reduces the need for transfusions

Study design1,2

PATIENTS DESIGN TREATMENT
  • Patients with anemia with non-myeloid malignancies recieving myelosuppressive chemotherapy
  • 344 patients randomized to PROCRIT® (n=174) or placebo (n=170) in a double-blind, 16-week clinical study
  • Patients received PROCRIT® 40,000 U (n=174) or placebo (n=170) SC QW
PATIENTS
  • Patients with anemia with non-myeloid malignancies recieving myelosuppressive chemotherapy
DESIGN
  • 344 patients randomized to PROCRIT® (n=174) or placebo (n=170) in a double-blind, 16-week clinical study
TREATMENT
  • Patients received PROCRIT® 40,000 U (n=174) or placebo (n=170) SC QW
QW=once weekly; SC=subcutaneously; U=units.

Selected safety profile1

WARNINGS: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

Cancer:

Expand the Important Safety Information at the bottom of the page to see the complete Boxed Warnings.

The adverse reactions with a reported incidence of ≥5% in PROCRIT®-treated patients that occurred at a higher frequency than in placebo-treated patients are shown in the table below:

Adverse reactions in patients with cancer1

ADVERSE REACTION PROCRIT®-treated patients (n=168) Placebo-treated patients (n=165)
NAUSEA 35% 30%
VOMITING 20% 16%
MYALGIA 10% 5%
ARTHRALGIA 10% 6%
STOMATITIS 10% 8%
COUGH 9% 7%
WEIGHT DECREASE 9% 5%
LEUKOPENIA 8% 7%
BONE PAIN 7% 4%
RASH 7% 5%
HYPERGLYCEMIA 6% 4%
INSOMNIA 6% 2%
HEADACHE 5% 4%
DEPRESSION 5% 4%
DYSPHAGIA 5% 2%
HYPOKALEMIA 5% 3%
THROMBOSIS 5% 3%

References

  1. PROCRIT® (epoetin alfa) Prescribing Information. Janssen Products, LP.
  2. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double–blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606-2617.
EXPAND